Evidence map›Paper›PMID 28004303›Full record

ArticleNeurochemical research2017

Silibinin ameliorates Aβ

Xiaoyu Song, Biao Zhou, Lingyu Cui, Di Lei, Pingping Zhang, Guodong Yao, Mingyu Xia, Toshihiko Hayashi, Shunji Hattori, Yuko Ushiki-Kaku and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Euxanthone Attenuates AβJournal of molecular neuroscience : MN · 2018
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Xiaoyu SongChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Biao ZhouChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Lingyu CuiChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Di LeiChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Pingping ZhangChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Guodong YaoChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Mingyu XiaChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Toshihiko HayashiChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Shunji HattoriNippi Research Institute of Biomatrix, Toride, Ibaraki, 302-0017, Japan.
Yuko Ushiki-KakuNippi Research Institute of Biomatrix, Toride, Ibaraki, 302-0017, Japan.
Shin-Ichi TashiroDepartment of Medical Education & Primary Care, Kyoto Prefectural University of Medicine, Kajiicho 465, Kamikyo-ku, Kyoto City, Kyoto, 602-8566, Japan.
Satoshi OnoderaDepartment of Clinical and Biomedical Sciences, Showa Pharmaceutical University, Tokyo, 194-8543, Japan.
Takashi IkejimaChina-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, China. ikejimat@vip.sina.com.
Shenyang Pharmaceutical University · CNJapan Institute of Leather Research · JPKyoto Prefectural University of Medicine · JPShowa Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disease. Accumulating evidence suggests that inflammatory response, oxidative stress and autophagy are involved in amyloid β (Aβ)-induced memory deficits. Silibinin (silybin), a flavonoid derived from the herb milk thistle, is well known for its hepatoprotective activities. In this study, we investigated the neuroprotective effect of silibinin on Aβ

Indexed as

Amyloid beta-PeptidesAnimalsAntioxidantsAutophagyDose-Response Relationship, DrugInflammationMaleMemory DisordersOxidative StressPeptide FragmentsRandom AllocationRatsRats, Sprague-DawleySilybinSilymarinAmyloid beta-Peptidesamyloid beta-protein (25-35)AntioxidantsPeptide FragmentsSilybinSilymarinAmyloid βAutophagyInflammatory responseOxidative stressSilibinin

Identifiers

PMID28004303
OpenAlexW2562311440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.